IVIS Spectrum Imaging System

描述(申请人提供)：光学成像正在迅速成为生物医学研究中最通用的成像方式之一。与其他成像方式相比，光学成像的优势包括非电离低能量辐射、对微米范围内的物体的高灵敏度以及在完整的环境中实时连续采集数据。与光学成像相关的成本、空间和时间要求低于其他成像方式，并且成像的速度和相对容易使该方式具有潜在的临床应用的吸引力。马萨诸塞州总医院(MGH)的阿蒂努拉·A·马蒂诺斯生物医学成像中心致力于开发和应用具有临床意义的突破性成像方法。我们的持续成功有赖于将新技术和新兴技术整合到我们现有的研究成像技术中，其中包括功能和高分辨率磁共振成像(fMRI和MRI)、脑磁图(MEG)、正电子发射断层扫描(PET)和自制的功能光学成像仪器。新技术增强了我们验证和解释来自现有成像资源的数据的能力，并将成像模式结合到新颖的多模式成像应用中-这是新兴的分子成像领域特别需要的能力。我们建议购买最先进的光学成像系统，能够在体内、体外和体外以透射式荧光、反射式荧光和生物发光模式进行3D分子成像。该系统可能采用的光学技术的显著优势包括：通过使用具有不同光谱特性的多个探头进行多通道成像的潜力；快速、容易且相对低成本地快速测试生物假说和在活体实验模型中的原理证明。重要的是，光学生物发光成像在检测极低水平的信号方面具有独特的优势，因为它几乎没有背景光发射。凭借其操作简单、采集时间短(通常为10-60秒)以及潜在的体外(微孔板)和体内(5只小鼠，23 cm视野)高通量格式，这一创新系统还提供了高通量成像能力。新的光学系统将成为许多目前资助的生物医学成像研究项目的重要资源。主要项目包括研究神经退行性疾病和脑功能、癌症、糖尿病和移植中的胰岛。有了新的在体光学成像系统和我们现有的成像设备在同一屋檐下，我们可以连续甚至并行使用一种或多种成像方式进行体内实验。对于Martinos中心和更大的MGH研究社区以及大波士顿地区的其他机构，该系统将成为丰富的跨学科研究机构的宝贵资源。 与公共健康相关：获得具有荧光和生物发光能力的最先进的活体光学成像系统将使人们能够以快速、简单和廉价的方式在活的实验模型中快速测试生物学假说和原理证明，这将进一步用于体内药物筛选、成像记者的开发以及癌症、神经疾病、糖尿病和心血管病理的多种动物研究。

DESCRIPTION (provided by applicant): Optical imaging is rapidly becoming one of the most versatile imaging modalities in biomedical research. The advantages of optical imaging compared to other imaging modalities include its non-ionizing low-energy radiation, high sensitivity for detecting objects in the micron range, and continuous data acquisition in real time and in an intact environment. The cost, space, and time demands associated with optical imaging are less than for other imaging modalities, and the speed and relative ease of imaging makes this modality attractive for potential clinical applications. The Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (MGH) strives to develop and apply breakthrough imaging approaches in clinically meaningful ways. Our continuing success relies on the integration of new and emerging technologies into our existing research imaging repertoire, which includes functional and high-resolution magnetic resonance imaging (fMRI and MRI), magnetoencephalography (MEG), positron emission tomography (PET), and homebuilt functional optical imaging instrumentation. New technologies enhance our ability to validate and interpret data from our existing imaging resources and to combine imaging modalities for novel multimodal imaging applications-capabilities that are particularly needed in the emerging field of molecular imaging. We propose to purchase a state-of-the-art optical imaging system capable of 3D molecular imaging in transmission fluorescence, reflectance fluorescence, and bioluminescence modes in vivo, ex vivo, and in vitro. Significant advantages of the optical techniques possible with this system include the potential for multichannel imaging by using multiple probes with different spectral characteristics; quick, easy, and relatively low-cost rapid testing of biological hypotheses and proofs of principle in living experimental models. Importantly, optical bioluminescence imaging has unique advantages for detection of very low levels of signal because of its virtually background-free light emission. With its ease of operation, short acquisition time (typically 10-60 sec), and potential high-throughput format in vitro (microplates) and in vivo (5 mice, 23 cm FOV), this innovative system also provides high-throughput imaging capabilities. The new optical system will be an important resource for many currently funded biomedical imaging research projects. Major projects include studies on neurodenenerative disorders and brain function, cancer, and pancreatic islets in diabetes and transplantation. With the new in vivo optical imaging system and our existing imaging facilities under one roof, we can feasibly perform in-vivo experiments using one or more imaging modalities in succession, or even in parallel. This system will be an invaluable resource for the rich body of interdisciplinary research at the Martinos center and the larger MGH research community, as well as at other institutions in the greater Boston area. PUBLIC HEALTH RELEVANCE: Acquiring of a state-of-the-art in vivo optical imaging system with fluorescence and bioluminescence capabilities will allow for fast, easy and cheap ways to rapidly test biological hypotheses and proofs of principle in living experimental models, which could be further utilized for in vivo drug screening, development of imaging reporters and versatile animal studies in cancer, neurological disorders, diabetes and cardiovascular pathologies.